Genetesis announces two abstracts selected for presentations at upcoming scientific meetings

Genetesis, a market leading biomagnetic imaging company, has announced that recent data collected in clinical study with the company’s lead product, CardioFlux was selected for abstract presentations at this year’s American College of Emergency Physicians (ACEP) Scientific Assembly later this month and at American Heart Association (AHA) Scientific Sessions in November.

These presentations will discuss the utility and improvements to standard of care when using CardioFlux as a diagnostic imaging solution to detect myocardial ischemia and diagnose coronary artery disease. The CardioFlux Magnetocardiograph has been designated a FDA Breakthrough Device for its potential benefits in improving and optimizing care in the triage process.

American College of Emergency Physicians (ACEP) Research Forum:

Title: Detection of Acute Coronary Syndrome by Magnetocardiography

Date and Time: Tuesday, October 26, 2021 at 11:00 a.m. ET

Session Name: RF 18 Abstract Session: Cardiovascular (ACS and non-ACS)

Session Type: Oral Abstract Session

Presenter: Sharon Mace, MD, FACEP, FAAP, Principal Investigator of ACCMED, Emergency Medicine Physician at Cleveland Clinic

Abstract #: 1145

American Heart Association (AHA) Scientific Sessions:

Title: A Novel Way to Predict Obstructive Coronary Artery Disease Requiring Revascularization: The Use of Magnetocardiography

Date: Saturday, November 13 – Monday, November 15, 2021

Session Name: Health Tech Posters II

Session Type: Abstract Poster Presentation

Presenter: Nicholas Coriasso, DO, Cardiology Fellow (PGY5) at Ascension St. John Hospital

Abstract #: 10642


Related News